WFA of San Diego LLC Acquires Shares of 2,450 Becton Dickinson and Co (NYSE:BDX)
WFA of San Diego LLC acquired a new stake in Becton Dickinson and Co (NYSE:BDX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,450 shares of the medical instruments supplier’s stock, valued at approximately $675,000.
A number of other large investors have also recently modified their holdings of BDX. Solstein Capital LLC acquired a new position in Becton Dickinson and in the first quarter worth $27,000. Balentine LLC boosted its holdings in Becton Dickinson and by 45.3% in the second quarter. Balentine LLC now owns 138 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 43 shares during the period. Watson Rebecca acquired a new position in Becton Dickinson and in the second quarter worth $36,000. Verus Capital Partners LLC boosted its holdings in Becton Dickinson and by 65.0% in the first quarter. Verus Capital Partners LLC now owns 165 shares of the medical instruments supplier’s stock worth $38,000 after purchasing an additional 65 shares during the period. Finally, Campbell Wealth Management acquired a new position in Becton Dickinson and in the second quarter worth $42,000. 84.18% of the stock is owned by institutional investors.
A number of equities research analysts have issued reports on BDX shares. UBS Group raised their target price on Becton Dickinson and from $265.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 10th. Raymond James raised their target price on Becton Dickinson and from $265.00 to $285.00 and gave the company an “outperform” rating in a research note on Friday, August 7th. They noted that the move was a valuation call. Zacks Investment Research cut Becton Dickinson and from a “hold” rating to a “sell” rating and set a $245.00 target price on the stock. in a research note on Wednesday, May 27th. William Blair reiterated an “outperform” rating on shares of Becton Dickinson and in a research note on Thursday, July 2nd. Finally, Morgan Stanley cut their target price on Becton Dickinson and from $285.00 to $270.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 27th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $279.47.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.04 by $0.16. Becton Dickinson and had a return on equity of 14.19% and a net margin of 5.30%. The company had revenue of $3.86 billion for the quarter, compared to analysts’ expectations of $3.96 billion. During the same quarter in the previous year, the business posted $3.08 EPS. The business’s revenue for the quarter was down 11.4% on a year-over-year basis. On average, sell-side analysts expect that Becton Dickinson and Co will post 9.9 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $3.16 annualized dividend and a yield of 1.39%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.05%.
In other Becton Dickinson and news, EVP Patrick Kaltenbach sold 1,272 shares of Becton Dickinson and stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $260.00, for a total transaction of $330,720.00. Following the transaction, the executive vice president now owns 10,340 shares of the company’s stock, valued at approximately $2,688,400. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.12% of the company’s stock.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: How to Use the New Google Finance Tool
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.